LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic

After Eli Lilly (LLY) posted earnings that outshined Novo Nordisk's (NVO) decelerating growth, Scott Zari feels comfortable calling Eli Lilly the dominant winner in the weight loss drug race. While he notes Novo Nordisk's pill as "important" to consumers, it's Eli Lilly's injectable he sees continuing to lead GLP-1 momentum. Tom White offers an example options trade for Eli Lilly.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6D

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

Follow us on X – https://twitter.com/schwabnetwork

Follow us on Facebook – https://www.facebook.com/schwabnetwork

Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/

About Schwab Network - https://schwabnetwork.com/about